Interestingly, the detection of a PIK3CA mutation in circulating tumor DNA in MBC patients treated with alpelisib was linked to significantly improved progression-free survival under treatment, suggesting a context-dependent activation of PI3K in metastatic processes [19]. Here, PIK3CB is linked to neoplasm.